Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry

Histopathology

Volumn 42, Issue 4, 2003, Pages 348-356

  Skálová, Alena ^a,g   Starek I ^b   Vanecek, T ^c   Kucerova V ^b   Plank, L ^d   Szepe P ^d   Di Palma, S ^e   Leivo, I ^f  

^a CHARLES UNIVERSITY   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c Faculty Hospital   (Czech Republic)

^d University Teaching Hospital in Martin   (Slovakia)

^e QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^f UNIVERSITY OF HELSINKI   (Finland)

^g CHARLES UNIVERSITY   (Czech Republic)

Author keywords

C erbB 2; FISH; HER 2 neu; Immunohistochemistry; Salivary duct carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR GENETICS; ONCOGENE NEU; PAROTID GLAND CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVARY GLAND CARCINOMA; SALIVARY GLAND DUCT; TREATMENT OUTCOME;

EID: 0345736008     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2003.01600.x     Document Type: Article

References (41)

1. Delgado R, Vuitch F, Albores-Saavedra J. Salivary duct carcinoma. Cancer 1993: 72; 1503-1512.
2. Hellquist HB, Karlsson MG, Nilsson C. Salivary duct carcinoma-a highly aggressive salivary gland tumour with overexpression of c-erbB-2. J. Pathol. 1994; 172: 35-44.
3. Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD. Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer 1996: 77; 223-230.
4. Martinez-Barba E, Cortes-Guardiola JA, Minguela-Puras A, Torroba-Caron A, Mendez-Trujillo S, Bermejo-Lopez J. Salivary duct carcinoma: clinicopathological and immunohistochemical studies. J. Craniomaxillofac. Surg. 1997: 25; 328-334.
5. De Potter CR. The neu-oncogene: more than a prognostic indicator? Hum. Pathol. 1994: 25; 1264-1268.
6. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989: 244; 707-712.
7. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998; 16; 413-428.
8. Vargas-Roig LM, Gago FE, Tello O, De Civetta MTM, Ciocca DR. C-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy. Int. J. Cancer (Pred. Oncol.) 1999: 84; 129-134.
9. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am. J. Clin. Pathol. 1999; 112(Suppl. 1); S53-67.
10. HER-2/neu monoclonal antibody plus cisplatin in patients with HER-2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Pathol. 1998; 16; 2659-2671.
11. Kernohan NM, Blessing K, King G, Corbett IP, Miller ID. Expression of c-erbB-2 oncoprotein in salivary gland tumours: an immunohistochemical study. J. Pathol. 1991; 163; 77-80.
12. Press MF, Pike MC, Hung G, Zhou JY, Ma Y, George J et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res. 1994; 54; 5675-5682.
13. Sugano S, Mukai K, Tsuda H, Hirohashi S, Furuza S, Shimosat Y et al. Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma. An indicator of aggressiveness. Laryngoscope 1992: 102; 923-927.
14. Jaehne M, Jakel KT, Roser K, Ussmuller J, Loning T. About the prognostic value of HER2 gene amplification and cell proliferation in salivary duct carcinoma of the major salivary glands-a pilot study. Laryngorhinootologie 2001; 80; 525-529.
15. Skálová A, Stárek I. Kucerová V. Szépe P, Plank L. Salivary duct carcinoma-a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. Path. Res. Pract. 2001: 197; 621-626.
16. Thomson TA, Hayes MM, Spinelli JJ et al. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod. Pathol. 2001; 14: 1079-1086.
17. Hermanová M, Nenutil R, Kroupová I, Brázdil J, Lukášová E, Kozubek S. Amplification and overexpression of HER-2/neu in invasive breast carcinomas: comparative analysis of immunohistochemical methods and fluorescence in situ hybridisation. Klin. Onkol. 2001; 14; 157-162.
18. Jacobs TW, Yaziji H, Gown AM, Barnes MJ, Schnitt SJ. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J. Clin. Oncol. 1999; 17; 1974-1982.
19. Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of HER-2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod. Pathol. 2000: 13: 37-45.
20. Simpson RHW, Clarke TJ, Sarsfield PTL, Babajews AV. Salivary duct adenocarcinoma. Histopathology 1991: 18; 229-235.
21. Fan CY, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma. An immunohistochemical analysis of 13 cases and review of the literature. Am. J. Surg. Pathol. 2000: 24; 579-586.
22. Kamio N. Coexpression of p53 and c-erbB-2 proteins is associated with histological type, tumor stage and cell proliferation in malignant salivary gland tumors. Virchows Arch. 1996: 428; 75-83.
23. Barnes L, Rao U, Krause J, Contis L, Schwartz A, Scalamogna P. Salivary duct carcinoma. Part II: immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D and c-erbB-2 protein. Oral Surg. Oral Med. Oral Pathol. 1994: 78; 74-80.
24. Felix A, El-Naggar AK. Press MF et al. Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum. Pathol. 1996; 27; 561-566.
25. Madrigal B, Garcia J, De Vicente JC. Salivary duct carcinoma: an unusual case of long-term evolution. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 1999; 88; 597-602.
26. Wick MR, Ockner DM, Mills SE, Ritter JH, Swanson PE. Homologous carcinomas of the breast, skin, and salivary glands. A histologic and immunohistochemical comparison of ductal mammary carcinoma, ductal sweat gland carcinoma, and salivary duct carcinoma. Am. J. Clin. Pathol. 1998: 109; 75-84.
27. Bánkfalvi A, Brandt RS, Burger H et al. Comparative methodological analysis of erbB-2/HER-2 gene dosage. chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. Histopathology 2000: 37; 411-419.
28. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J. Clin. Oncol. 1999: 17; 1983-1987.
29. Espinoza F. HercepTest assay. Another perspective. J. Clin. Oncol. 1999: 17; 2293-2294.
30. Barry MB, Robinson RA, DeYoung BR. Her-2neu expression in salivary duct carcinoma: an immunohistochemical analysis. Mod. Pathol. 2001: 148A; (Abstr.).
31. Kay PA, Roche PC, Olsen KD, Lewis JE. Salivary duct carcinoma: immunohistochemical analysis of androgen receptor, prostatic markers and HER-2/neu oncoprotein in 40 cases. Mod. Pathol. 2001: 150A; (Abstr.).
32. Farabegoli F, Ceccarelli C, Santini D et al. C-erbB over-expression in amplified and non-amplified breast carcinoma samples. Int. J. Cancer 1999: 84; 273-277.
33. Onody P, Bertrand F, Muzeau F, Bieche I, Lidereau R. Fluorescence in situ hybridization and immunohistochemical assays for HER-2/neu status determination. Application to node-negative breast cancer. Arch. Pathol. Lab. Med. 2001: 125; 746-750.
34. Thor A. HER2-a discussion of testing approaches in the USA. Ann. Oncol. 2001: 12(Suppl. 1); S101-107.
35. Wang S, Saboorian H, Frenkel EP et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod. Pathol. 2002: 15; 137-145.
36. Kapadia SB, Barnes L. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma. Mod. Pathol. 1998: 11; 1033-1038.
37. Skálová A. Leivo I, Boguslawsky K, Saksela E. Cell proliferation correlates with prognosis in acinic cell carcinomas of salivary gland origin. Immunohistochemical study of 30 cases using the MIB 1 antibody in formalin-fixed paraffin sections. J. Pathol. 1994: 173; 13-21.
38. Skálová A, Lehtonen H, Boguslawsky K, Leivo I. Prognostic significance of cell proliferation in mucoepidermoid carcinomas of salivary gland. Clinicopathological study using MIB 1 antibody in paraffin sections. Hum. Pathol. 1994; 25; 929-935.
39. Lewis JE, Olsen KD, Sebo TJ. Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. Hum. Pathol. 2001: 32; 596-604.
40. Muller S, Wigneswaran N, Gansler T et al. C-erbB-2 oncoprotein expression and amplification in pleomorphic adenoma and carcinoma ex pleomorphic adenoma. Relationship to prognosis. J. Pathol. 1994: 7; 628-632.
41. Rosa JC, Fonseca J, Felix A et al. Immunohistochemical study of c-erbB-2 expression in carcinoma ex pleomorphic adenoma. Histopathology 1996; 28; 247-252.